Skip to main content

Table 2 Reported adverse events in the double-blinded, placebo-controlled trials only.

From: Atosiban versus betamimetics in the treatment of preterm labour in Germany: an economic evaluation

Adverse event Frequency (%)
Atosiban
Frequency (%)
Betamimetics
Relative risk and Confidence Intervals p-value
Tachycardia 5.50% 75.50% RR = 0.07,
95% CI = 0.05, 0.11
<0.001
Palpitation 2.20% 15.60% RR = 0.15,
95% CI = 0.07, 0.3
<0.001
Vomiting 6.90% 21.80% RR = 0.31,
95% CI = 0.21, 0.48
<0.001
Headache 9.70% 18.60% RR = 0.52,
95% CI = 0.35, 0.76
<0.001
Hyperglycaemia 6.40% 12.40% RR = 0.53,
95% CI = 0.38, 0.85
0.008
Tremor 1.40% 15.90% RR = 0.09,
95% CI = 0.04, 0.22
<0.001
Nausea 11.90% 15.90% RR = 0.75,
95% CI = 0.52, 1.08
0.121
Dyspnoea 0.30% 7.30% RR = 0.07,
95% CI = 0.02, 0.3
<0.001
Chest pain 1.10% 4.80% RR = 0.22,
95% CI = 0.08, 0.65
0.006
Hypokalemia 0.80% 6.50% RR = 0.15,
95% CI = 0.05, 0.45
<0.001
Hypotension 3.30% 5.70% RR = 0.59,
95% CI = 0.29, 1.16
0.127
Anxiety 1.10% 2.40% RR = 0.46,
95% CI = 0.15, 1.48
0.195
Syncope 0.60% 0.50% RR = 1.02,
95% CI = 0.17, 5.98
0.984
Pulmonary oedema 0.30% 0.50% RR = 0.6,
95% CI = 0.08, 4.45
0.614
Myocardial ischemia 0.00% 0.30% RR = 0.34,
95% CI = 0.01, 8.3
0.509
Foetal tachycardia 3.30% 27.70% RR = 0.13,
95% CI = 0.07, 0.26
<0.001